Newsroom

Sorted by: Latest
-

AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts

TALLAHASSEE, Fla.--(BUSINESS WIRE)--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts...
-

Harvest Care Medical Completes DEA Registration Across Entire Cannabis Operations

BRIDGEPORT, W. Va.--(BUSINESS WIRE)--Harvest Care Medical today announced the successful completion of its U.S. Drug Enforcement Administration (DEA) registration process for all of its licensed cannabis operations, including 10 dispensaries, one cultivation facility, and one processing facility. The milestone further strengthens the company’s regulatory compliance framework and positions Harvest Care Medical for continued operational excellence and future growth. The completion of DEA registra...
-

Over 100 long-term care workers rally for better working conditions and wages as for-profit corporation stonewalls in negotiations

Markham, ON--(BUSINESS WIRE)--On Monday, June 29, over 100 long-term care workers from across the province boarded buses to hold a rally at Extendicare’s head office in Markham. Eight CUPE local unions representing 1,100 long-term care staff are currently in bargaining with Extendicare. The employees are calling on the for-profit corporation to address chronic understaffing, low wages and inadequate benefits - issues directly tied to resident care. Extendicare previously withdrew from talks in...
-

Samsung Bioepis gibt positive vorläufige Phase-1- und Phase-3-Daten für SB27 bekannt, ein geplantes Biosimilar zu Keytruda (Pembrolizumab)

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass die Phase-1- und Phase-3-Studien zu SB27, einem geplanten Biosimilar zu Keytruda1 (Pembrolizumab), ihre primären Endpunkte erreicht haben. „Wir freuen uns, vorläufige Ergebnisse aus den Phase-1- und Phase-3-Studien zu SB27, unserem Pembrolizumab-Biosimilar-Kandidaten, bekannt zu geben. Diese positiven Topline-Ergebnisse untermauern unsere wissenschaftliche Kompetenz und unsere Führungsrolle in der Entwicklung von...
-

Samsung Bioepis anuncia dados preliminares positivos das Fases 1 e 3 para o SB27, um biossimilar proposto para o Keytruda (Pembrolizumabe)

INCHEON, Coreia--(BUSINESS WIRE)--A Samsung Bioepis Co., Ltd. anunciou hoje que os estudos de Fase 1 e Fase 3 sobre o SB27, um biossimilar proposto para o Keytruda1 (pembrolizumabe), atingiram seus desfechos primários. “Temos o prazer de anunciar os resultados preliminares dos estudos de Fase 1 e Fase 3 do SB27, nosso candidato a biossimilar de pembrolizumabe. Esses resultados positivos iniciais reforçam nossa expertise científica e nossa liderança no desenvolvimento de biossimilares”, afirmou...
-

Samenvatting: Samsung Bioepis kondigt positieve voorlopige gegevens uit Fase 1 en Fase 3 aan voor SB27, een voorgestelde biosimilar voor Keytruda (pembrolizumab)

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. maakte vandaag bekend dat de Fase 1- en Fase 3-studies van SB27, een voorgestelde biosimilar voor Keytruda (pembrolizumab), aan hun primaire eindpunten voldoet. “We zijn enthousiast om de voorlopige resultaten uit de Fase 1- en Fase 3-studies aan te kondigen voor SB27, ons biosimilaire kandidaatgeneesmiddel voor pembrolizumab. Deze positieve eerste resultaten versterken onze wetenschappelijke expertise en leiderschap in de ontwikkeling...
-

Inside the $63 Million Investment Modernizing Over 1,700 Fort Sill Homes

FORT SILL, Okla.--(BUSINESS WIRE)--Corvias recently brought together dozens of Army leaders, congressional representatives, and partners to showcase a $63 million investment focused on improving resident comfort and installation resilience at Fort Sill. The project upgrades over 1,700 military family homes with high-efficiency geothermal heating and cooling, smart thermostats, new hot water systems, and advanced controls. The work is expected to cut annual energy use across the Fort Sill housin...
-

Dichiarazione di Seiden Law LLP: l'uomo d'affari cambogiano Leak Yim, erroneamente accusato in Thailandia, chiede giustizia presso un tribunale degli Stati Uniti

SINGAPORE--(BUSINESS WIRE)--Seiden Law LLP ("Seiden Law"), consulente legale del Sig. Leak Yim, di nazionalità cambogiana, e della sua famiglia, ha reso noto di aver depositato presso il tribunale federale del distretto di Washington D.C. un'istanza per l'ottenimento di un'autorizzazione giudiziaria mirata ad accertare le informazioni false e fuorvianti che potrebbero aver portato all'erronea incriminazione in Thailandia del Sig. Yim, oltre che alla sua ingiustificata identificazione al Congres...
-

FUTU DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Futu Holdings Limited (FUTU) Investors of Securities Class Action Lawsuit Deadline on August 25, 2026

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ: FUTU) and reminds investors of the August 25, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h...
-

Samsung Bioepis annonce des résultats préliminaires positifs de phase 1 et de phase 3 pour SB27, un biosimilaire proposé de Keytruda (pembrolizumab)

INCHEON, Corée--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. a annoncé aujourd’hui que les études de phase 1 et de phase 3 portant sur SB27, un biosimilaire proposé de Keytruda1 (pembrolizumab), avaient atteint leurs critères d’évaluation principaux. « Nous sommes ravis d’annoncer les résultats préliminaires des études de phase 1 et de phase 3 concernant SB27, notre candidat biosimilaire du pembrolizumab. Ces résultats préliminaires positifs renforcent notre expertise scientifique et notre leader...